Protalix BioTherapeutics, Inc.
General ticker "PLX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $154.5M (TTM average)
Protalix BioTherapeutics, Inc. does not follow the US Stock Market performance with the rate: -5.1%.
Estimated limits based on current volatility of 2.9%: low 1.68$, high 1.78$
Factors to consider:
- Total employees count: 213 (+2.4%) as of 2024
- Top business risk factors: Product development and market acceptance, Regulatory and compliance, Operational and conduct risks, Supply chain disruptions, Market competition
- Price in estimated range
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [1.45$, 3.19$]
- 2025-12-31 to 2026-12-31 estimated range: [1.56$, 3.35$]
Financial Metrics affecting the PLX estimates:
- Positive: with PPE of 59.6 at the end of fiscal year the price was very low
- Positive: -3.60 < Operating profit margin, % of 7.34
- Negative: negative Industry operating cash flow (median)
- Positive: 1.87 < Return on assets ratio (scaled to [-100,100]) of 3.84
- Positive: 41.86 < Shareholder equity ratio, % of 58.86 <= 63.39
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: Investing cash flow per share per price, % of 3.25 > -0.66
Short-term PLX quotes
Long-term PLX plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $47.64MM | $65.49MM | $53.40MM |
| Operating Expenses | $60.65MM | $55.03MM | $49.48MM |
| Operating Income | $-13.01MM | $10.46MM | $3.92MM |
| Non-Operating Income | $-1.38MM | $-1.89MM | $0.24MM |
| R&D Expense | $29.35MM | $17.09MM | $12.97MM |
| Income(Loss) | $-14.40MM | $8.57MM | $4.15MM |
| Taxes | $0.53MM | $0.25MM | $1.22MM |
| Profit(Loss)* | $-14.93MM | $8.31MM | $2.93MM |
| Stockholders Equity | $-10.64MM | $33.57MM | $43.21MM |
| Inventory | $16.80MM | $19.05MM | $21.24MM |
| Assets | $55.79MM | $84.43MM | $73.42MM |
| Operating Cash Flow | $-25.00MM | $-1.32MM | $8.67MM |
| Capital expenditure | $0.63MM | $1.15MM | $1.28MM |
| Investing Cash Flow | $-5.04MM | $-16.71MM | $4.22MM |
| Financing Cash Flow | $8.24MM | $24.67MM | $-16.79MM |
| Earnings Per Share** | $-0.31 | $0.12 | $0.04 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.